

Therapeutic Anticoagulation with Heparin in Critically

New England Journal of Medicine

385, 777-789

DOI: [10.1056/nejmoa2103417](https://doi.org/10.1056/nejmoa2103417)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. <i>Cardiovascular Research</i> , 2021, 117, 2807-2820.	1.8	21
2	Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. <i>JMIR Medical Informatics</i> , 2021, 9, e30743.	1.3	3
3	Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1533-1545.	1.9	21
4	Anticoagulation in COVID-19: reaction to the ACTION trial. <i>Lancet, The</i> , 2021, 397, 2226-2228.	6.3	14
5	Pulmonary Thrombosis and Thromboembolism in COVID-19. <i>Chest</i> , 2021, 160, 1471-1480.	0.4	92
6	COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year. <i>Lancet Haematology</i> , 2021, 8, e524-e533.	2.2	174
7	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	2.3	30
8	Heparin —“Messias or Verschlimmbesserung?”. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2373-2382.	1.9	8
9	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
11	Thromboembolism and Bleeding in COVID-19. <i>J</i> , 2021, 4, 476-485.	0.6	1
12	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1387-1395.	5.2	259
13	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9.	2.3	31
14	Surviving Covid-19 with Heparin?. <i>New England Journal of Medicine</i> , 2021, 385, 845-846.	13.9	54
15	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
16	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
17	Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. <i>EClinicalMedicine</i> , 2021, 40, 101125.	3.2	53
18	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2022, 28, 93-112.	0.7	15
19	Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	5

#	ARTICLE	IF	CITATIONS
20	Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an "old" strategy. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000867.	1.2	17
21	Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Stroke</i> , 2021, 52, 3045-3053.	1.0	38
22	Cardiovascular implications of the COVID-19 pandemic. <i>Journal of Cardiology</i> , 2022, 79, 460-467.	0.8	7
23	Lung microbiota and COVID-19 severity. <i>Nature Microbiology</i> , 2021, 6, 1217-1218.	5.9	10
24	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
25	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559.	1.3	27
26	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3
27	Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19. <i>Chest</i> , 2022, 161, 710-727.	0.4	36
28	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906.	1.1	1
29	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. <i>Anesthesiology</i> , 2021, 135, 1076-1090.	1.3	3
30	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. <i>EClinicalMedicine</i> , 2021, 41, 101139.	3.2	19
31	Prevention of venous thromboembolism in COVID-19 patients: Is there a way forward?. <i>Vascular Investigation and Therapy</i> , 2021, 4, 83.	0.3	1
32	Anticoagulation is the answer in treating noncritical COVID-19 patients. <i>Open Medicine (Poland)</i> , 2021, 16, 1486-1492.	0.6	4
34	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157.	0.6	11
35	Antithrombotic Therapy for Outpatients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1685.	3.8	3
36	Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. <i>British Journal of Haematology</i> , 2022, 196, 566-576.	1.2	27
37	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
38	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 295-299.	1.8	40

#	ARTICLE	IF	CITATIONS
39	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400.	3.0	250
40	The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2536-2543.	0.6	4
41	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.	1.2	49
42	What went wrong: A reckoning of Canada's contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic. <i>Jammi</i> , 2021, 6, 241-244.	0.3	2
43	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
44	Complications of Critical COVID-19. <i>Chest</i> , 2022, 161, 989-998.	0.4	14
45	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1612.	2.6	326
46	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 – Authors' reply. <i>Lancet, The</i> , 2021, 398, 1304.	6.3	0
48	Anticoagulant Therapy in Patients Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1621.	2.6	11
49	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 17-31.	1.9	45
50	Glucocorticoid Dose in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1801.	3.8	8
51	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. <i>International Journal of Cardiology</i> , 2021, 344, 240-245.	0.8	17
52	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	1.5	4
53	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1703.	3.8	186
54	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. <i>Thrombosis Research</i> , 2021, 208, 35-38.	0.8	1
55	SOFA Score as a Reliable Tool to Detect High Risk for Venous Thrombosis in Patients With Critical Stage SARS-CoV-2. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 729298.	1.1	3
56	A Case of COVID-19-Associated Free-Floating Aortic Thrombus Successfully Treated with Thrombectomy. <i>American Journal of Case Reports</i> , 2021, 22, e933225.	0.3	6
57	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	1

#	ARTICLE	IF	CITATIONS
58	Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110488.	0.7	9
61	Dilemma of Anticoagulation Therapy in Mild or Asymptomatic COVID-19 Cases. <i>Cureus</i> , 2021, 13, e19291.	0.2	2
62	Host-modifying drugs against COVID-19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270.	1.8	0
63	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
64	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. <i>American Journal of the Medical Sciences</i> , 2022, 363, 465-475.	0.4	16
65	COVID-19 critical illness in pregnancy. <i>Obstetric Medicine</i> , 2022, 15, 220-224.	0.5	3
66	Clinical practice guideline: Recommendations on the in-hospital treatment of patients with COVID-19. <i>Deutsches Arzteblatt International</i> , 2021, , .	0.6	15
67	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 767074.	1.1	20
68	Therapeutic Anticoagulation with Heparin in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 2013-2014.	13.9	1
69	ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238.	2.8	103
70	Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2022, 10, 803-810.	0.9	5
71	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. <i>Thrombosis Journal</i> , 2021, 19, 91.	0.9	12
72	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. <i>European Heart Journal</i> , 2022, 43, 365-366.	1.0	0
73	Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 5652.	1.0	2
74	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 257-265.	0.8	18
75	Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study. <i>Journal of Intensive Care Medicine</i> , 2021, , 088506662110519.	1.3	3
76	Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding. <i>Viruses</i> , 2021, 13, 2278.	1.5	10
77	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. <i>European Journal of Internal Medicine</i> , 2022, 96, 13-16.	1.0	9

#	ARTICLE	IF	CITATIONS
79	Coronavirus disease 2019 and cardiovascular diseases. <i>Current Opinion in Anaesthesiology</i> , 2021, Publish Ahead of Print, .	0.9	5
80	Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19. <i>TH Open</i> , 2022, 06, e21-e25.	0.7	9
81	Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding. <i>Journal of Clinical Medicine</i> , 2021, 10, 5369.	1.0	7
82	High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5549.	1.0	13
83	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. <i>Lancet Respiratory Medicine</i> , 2022, 10, 214-220.	5.2	37
84	Intubation to Nowhere in COVID-19. <i>Mayo Clinic Proceedings</i> , 2022, 97, 4-6.	1.4	2
85	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
87	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet</i> , 2022, 399, 143-151.	6.3	199
88	Global lessons learned from COVID-19 mass casualty incidents. <i>British Journal of Anaesthesia</i> , 2022, 128, e97-e100.	1.5	7
89	Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. <i>International Journal of Cardiology</i> , 2022, 349, 157-165.	0.8	10
90	Randomised clinical trials in critical care: past, present and future. <i>Intensive Care Medicine</i> , 2022, 48, 164-178.	3.9	46
91	Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 614-623.	2.3	20
92	Acute Circulatory Collapse and Advanced Therapies in Patients with COVID-19 Infection. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 43-52.	0.5	2
93	Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 17, 63-72.	0.5	2
94	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. <i>American Heart Journal</i> , 2022, 246, 136-143.	1.2	8
95	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 1-13.	0.9	16
96	Interpreting recent clinical studies for COVID-19: A continual process with more new data. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, 41, 101016.	0.6	3
97	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study. <i>Clinics</i> , 2021, 76, e3547.	0.6	13

#	ARTICLE	IF	CITATIONS
98	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180
99	Efficacy and safety of therapeutic vs. prophylactic bempirarin in noncritically ill patients with COVID-19 pneumonia. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	3
100	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. <i>Vaccines</i> , 2022, 10, 192.	2.1	20
101	Potential therapeutic options for COVID-19: an update on current evidence. <i>European Journal of Medical Research</i> , 2022, 27, 6.	0.9	85
102	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	14
103	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Nonâ€œCritically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	3.8	89
104	COVID-19:Â:Âles thÃ©rapeutiques. , 2022, 1, 13-13.		0
105	Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19. , 2022, 4, e0618.		5
106	Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials. , 2022, 19, .		1
107	Anticoagulation in COVID-19. <i>Lancet, The</i> , 2022, 399, 5-7.	6.3	18
108	Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12645.	1.0	5
109	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
110	Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation. <i>Critical Care Medicine</i> , 2022, Publish Ahead of Print, .	0.4	33
111	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784505.	1.8	5
112	COVID-19 and Elevated D-Dimer: A Tale of Caution. <i>Journal of General Internal Medicine</i> , 2022, 37, 1304-1305.	1.3	1
113	COVID-19 in the Critically Ill Pregnant Patient. <i>Critical Care Clinics</i> , 2022, , .	1.0	5
114	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 802566.	1.1	7
115	Methylprednisolone, venous thromboembolism, and association with heparin to 30Â:days in hospital survival in severe Covid-19 pneumonia. <i>BMC Pulmonary Medicine</i> , 2022, 22, 6.	0.8	5

#	ARTICLE	IF	CITATIONS
116	COVID-19 and Acute Kidney Injury. <i>Critical Care Clinics</i> , 2022, 38, 473-489.	1.0	21
117	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 50-59.	6.3	172
118	Fibrinolytics as an ARDS Salvage Option. <i>Chest</i> , 2022, 161, 595-596.	0.4	0
119	Upper extremity deep vein thrombosis in COVID-19: Incidence and correlated risk factors in a cohort of non-ICU patients. <i>PLoS ONE</i> , 2022, 17, e0262522.	1.1	8
120	COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort. <i>PLoS ONE</i> , 2022, 17, e0261786.	1.1	17
121	The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 817305.	1.2	7
122	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Scoreâ€”Matched Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 352.	1.0	10
123	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	15.2	206
125	Effects of dalteparin on antiâ€”Xa activities cannot be predicted in critically ill COVIDâ€”19 patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	4
126	Thromboprophylaxis for COVID-19-related coagulopathy: what next?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	1.4	1
127	SARSâ€”CoVâ€”2â€”related and Covidâ€”19 vaccineâ€”induced thromboembolic events: A comparative review. <i>Reviews in Medical Virology</i> , 2022, 32, e2327.	3.9	8
128	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 389-393.	0.6	1
129	Nonâ€”severe COVIDâ€”19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1008-1014.	1.9	18
130	Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched studyâ€”Reply to comment from Muzaffar et al.. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
131	Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19. <i>Future Science OA</i> , 2022, 8, FSO777.	0.9	1
132	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 808221.	1.2	6
133	Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis. <i>Thrombosis Update</i> , 2022, 6, 100096.	0.4	2
134	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100101.	0.6	8

#	ARTICLE	IF	CITATIONS
135	Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19. <i>Thrombosis Update</i> , 2022, 6, 100097.	0.4	1
136	Multi-organ point-of-care ultrasound for detection of pulmonary embolism in critically ill COVID-19 patients – A diagnostic accuracy study. <i>Journal of Critical Care</i> , 2022, 69, 153992.	1.0	5
137	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297
138	COVID-19 Coagulopathy: From Pathogenesis to Treatment. <i>Acta Haematologica</i> , 2022, 145, 282-296.	0.7	19
140	Thrombosis pathways in COVID-19 versus influenza-associated ARDS: a targeted proteomics approach. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	4
141	Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225.	0.4	58
142	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043.	0.4	4
143	Regional citrate and systemic heparin are adequate to maintain filter half-life for COVID-19 patients on continuous renal replacement therapy. <i>Seminars in Dialysis</i> , 2022, , .	0.7	2
144	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, .	2.9	146
145	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. <i>Thrombosis Research</i> , 2022, 211, 114-122.	0.8	5
146	The association of anticoagulation before admission and survival of patients with COVID-19. <i>Journal of Cardiology</i> , 2022, 79, 489-493.	0.8	4
147	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28.	1.3	5
148	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.4	7
149	Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 507-519.	2.5	56
150	Neck Circumference Predicts Mortality in Hospitalized COVID-19 Patients. <i>Infectious Disease Reports</i> , 2021, 13, 1053-1060.	1.5	3
151	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. <i>Viruses</i> , 2021, 13, 2486.	1.5	10
152	Heparin-induced thrombocytopenia in COVID-19: A systematic review. <i>Anesthesia: Essays and Researches</i> , 2021, 15, 341.	0.2	4
153	Anticoagulants and corticosteroids in COVID-19: What do we know so far?. <i>Srpski Medicinski Āasopis Lekarske Komore</i> , 2022, 3, 62-74.	0.1	1

#	ARTICLE	IF	CITATIONS
154	Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210862.	0.7	2
155	â€œMATH+â€•Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 53-79.	0.6	4
156	A year in review in <i>Minerva Anestesiologica</i> 2021. <i>Critical care. Minerva Anestesiologica</i> , 2022, 88, 89-100.	0.6	0
157	Multicenter STudy of tissue plasminogen activator (alteplase) use in COVIDâ€•19 severe respiratory failure (MUST COVID): Aâ€•retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12669.	1.0	6
160	COVIDâ€•19 and venous thromboembolism: A narrative review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12666.	1.0	16
161	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <i>Critical Care Clinics</i> , 2022, , .	1.0	6
162	European Society of Cardiology Highlights: Late-breaking Trials â€• COVID-19. <i>European Cardiology Review</i> , 2022, 17, e04.	0.7	0
163	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. <i>Antibiotics</i> , 2022, 11, 241.	1.5	4
164	Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2961-2967.	0.6	4
165	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 807934.	2.2	24
166	Low versus high dose anticoagulation in patients with Coronavirus 2019 pneumonia at the time of admission to critical care units: A multicenter retrospective cohort study in the Beaumont healthcare system. <i>PLoS ONE</i> , 2022, 17, e0265966.	1.1	2
167	Full <i>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. <i>Haematologica</i> , 2022, 107, 1933-1939.	1.7	5
168	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.4	6
171	Impact of Thromboprophylaxis Intensity on Patientsâ€™ Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study. <i>Clinical Epidemiology</i> , 2022, Volume 14, 361-368.	1.5	1
172	Clinical Evidence Generation During a Pandemic. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 151-156.	1.0	2
173	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate. <i>Frontiers in Immunology</i> , 2022, 13, 868679.	2.2	7
174	Cardiovascular drugs and COVIDâ€•19 clinical outcomes: a systematic review and metaâ€•analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3577-3599.	1.1	7
175	Successful treatment of intracardiac thrombosis in the presence of fulminant myocarditis requiring ECMO associated with COVID-19. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 849-851.	0.3	1

#	ARTICLE	IF	CITATIONS
176	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. <i>EBioMedicine</i> , 2022, 77, 103893.	2.7	48
178	Immunothrombosis and the molecular control of tissue factor by pyroptosis: prospects for new anticoagulants. <i>Biochemical Journal</i> , 2022, 479, 731-750.	1.7	9
179	What Are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine?. <i>Circulation</i> , 2022, 145, 629-632.	1.6	19
180	Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: a narrative review of current literature. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 3312-3317.	0.6	6
181	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	1.9	7
182	Anticoagulation in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2022, 79, 917-928.	1.2	35
183	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3338.	1.8	11
184	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. <i>Chest</i> , 2022, 161, 1446-1448.	0.4	8
185	The Future of Critical Care: Optimizing Technologies and a Learning Healthcare System to Potentiate a More Humanistic Approach to Critical Care. , 2022, 4, e0659.		11
186	Coreceptor functions of cell surface heparan sulfate proteoglycans. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 322, C896-C912.	2.1	20
187	Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients. <i>Scientific Reports</i> , 2022, 12, 4801.	1.6	10
188	Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1291.e1-1291.e5.	2.8	3
190	In Situ Pulmonary Thrombolysis and Perfusion Lung Angiography in Severe COVID-19 Respiratory Failure. , 2022, 4, e0670.		0
191	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. <i>Infection</i> , 2022, 50, 1453-1463.	2.3	4
192	Rebuttal From Dr David Jimenez et al. <i>Chest</i> , 2022, 161, 1453-1455.	0.4	0
193	Role of Acute Thrombosis in COVID-19. <i>Critical Care Clinics</i> , 2022, , .	1.0	3
195	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. <i>Frontiers in Microbiology</i> , 2022, 13, 860931.	1.5	15
196	Shining a light on platelet activation in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	3

#	ARTICLE	IF	CITATIONS
197	Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial. <i>Critical Care Research and Practice</i> , 2022, 2022, 1-10.	0.4	1
198	Extracardiac Prothrombotic Effects of COVID-19. <i>Cardiology Clinics</i> , 2022, , .	0.9	2
200	Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12683.	1.0	4
201	Challenging management dogma where evidence is non-existent, weak or outdated. <i>Intensive Care Medicine</i> , 2022, 48, 548-558.	3.9	10
202	D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes. <i>PLoS Pathogens</i> , 2022, 18, e1010468.	2.1	7
203	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
204	Thromboinflammation and Antithrombotics in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1234.	3.8	9
205	Association between pre-admission anticoagulation and in-hospital death, venous thromboembolism, and major bleeding among hospitalized COVID-19 patients in Japan. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 680-688.	0.9	5
206	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. <i>Journal of Cardiology</i> , 2022, 80, 285-291.	0.8	18
207	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
208	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. <i>Thrombosis Research</i> , 2022, 213, 173-178.	0.8	12
209	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170.	0.7	13
210	(Acute pulmonary embolism). <i>Cor Et Vasa</i> , 2021, 63, 675-682.	0.1	0
212	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 264-271.	0.6	12
214	Efficacy and Safety of Anticoagulation Treatment in COVID-19 Patient Subgroups Identified by Clinical-Based Stratification and Unsupervised Machine Learning: A Matched Cohort Study. <i>Frontiers in Medicine</i> , 2021, 8, 786414.	1.2	2
215	Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19. <i>Hospital Pharmacy</i> , 0, , 001857872110664.	0.4	1
216	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	1.0	39
217	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6

#	ARTICLE	IF	CITATIONS
218	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12944.	1.2	19
219	Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The COVID-19 Randomized Trial. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13735.	1.7	31
220	Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	2
221	An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 365-374.	0.7	3
222	Clinical features and acute management of COVID-19 in adults. , 2021, , 101-123.		2
223	Prone Positioning as a Potential Risk Factor for Deep Vein Thrombosis in COVID-19 Patients: A Hypothesis Generating Observation. <i>Journal of Clinical Medicine</i> , 2022, 11, 103.	1.0	2
224	Venous Thrombosis and SARS-CoV-2. <i>Hamostaseologie</i> , 2022, 42, 240-247.	0.9	7
225	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158.	4.6	22
227	Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 57.	1.0	11
228	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103529.	2.0	22
229	Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. <i>BMJ</i> , The, 2022, 376, e068407.	3.0	30
230	Lessening Organ Dysfunction With Vitamin C (LOVIT) Trial: Statistical Analysis Plan. <i>JMIR Research Protocols</i> , 2022, 11, e36261.	0.5	3
231	First do no harm. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12694.	1.0	2
232	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 100, 21-24.	1.0	7
233	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. <i>Journal of Virology</i> , 2022, 96, e0005722.	1.5	14
234	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients. <i>American Journal of Therapeutics</i> , 2022, Publish Ahead of Print, .	0.5	0
235	New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19—A Large Postmortem and Clinical Analysis. <i>Viruses</i> , 2022, 14, 811.	1.5	3
236	COVID-19 and Cardiac Arrhythmias: a Contemporary Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 87-107.	0.4	15

#	ARTICLE	IF	CITATIONS
237	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. <i>Seminars in Immunopathology</i> , 2022, 44, 375-390.	2.8	15
238	Acute Arterial Occlusions in COVID-19 Times: A Comparison Study Among Patients with Acute Limb Ischemia With or Without COVID-19 Infection. <i>Annals of Vascular Surgery</i> , 2022, 83, 80-86.	0.4	3
239	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 399-419.	1.0	1
240	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 062-072.	1.5	13
241	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 817-822.	0.7	3
242	Epidemiology and Management of STâ€Segmentâ€Elevation Myocardial Infarction in Patients With COVIDâ€19: A Report From the American Heart Association COVIDâ€19 Cardiovascular Disease Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024451.	1.6	6
243	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. <i>Journal of Intensive Care Medicine</i> , 2022, 37, 1238-1249.	1.3	3
244	Clinical features of thrombosis and bleeding in COVID-19. <i>Blood</i> , 2022, 140, 184-195.	0.6	29
245	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
246	Critically ill COVID-19 patients in northeast Brazil: mortality predictors during the first and second waves including SAPS 3. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 1054-1062.	0.7	4
247	Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. <i>Neurology International</i> , 2022, 14, 391-405.	1.3	25
248	Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. <i>Chest</i> , 2022, 162, 804-814.	0.4	10
250	Use of Anticoagulants in COVID-19: A Review. <i>American Journal of Therapeutics</i> , 2022, 29, e425-e436.	0.5	4
251	Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. <i>Pediatrics</i> , 2022, 150, .	1.0	19
252	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 573-583.	2.5	16
254	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	3
256	Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study. <i>BMC Infectious Diseases</i> , 2022, 22, 462.	1.3	17
258	Critical Care Management of Severe COVID-19 in Pregnant Patients. <i>Cureus</i> , 2022, 14, e24885.	0.2	0

#	ARTICLE	IF	CITATIONS
259	Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. PLoS ONE, 2022, 17, e0266944.	1.1	4
260	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 2695.	1.0	4
261	Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. Frontiers in Surgery, 2022, 9, .	0.6	23
262	Plasma Proteomics of COVID-19 Associated Cardiovascular Complications. JACC Basic To Translational Science, 2022, 7, 425-441.	1.9	17
263	COVID-19 associated rhabdomyolysis leading to major amputation in the absence of macrovascular thrombosis. Annals of Vascular Surgery Brief Reports and Innovations, 2022, 2, 100082.	0.1	2
266	Venous and arterial thrombosis in COVID-19: An updated narrative review. Journal of Infection and Public Health, 2022, 15, 689-702.	1.9	6
267	Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. BMJ Open, 2022, 12, e059383.	0.8	3
268	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 730-739.	2.5	10
269	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 2022, 54, 197-210.	1.0	29
270	Endothelial dysfunction and thrombotic events in patients with severe novel coronavirus infection COVID-19. Uchenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2022, 28, 38-47.	0.0	3
271	Diagnosis and management of covid-19 in pregnancy. BMJ, The, 2022, 377, e069739.	3.0	25
272	Double Jeopardy: Precapillary Pulmonary Hypertension Increases the Risk of Hospitalization and Death from COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	0
273	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	18
274	COVID-19 associated coagulopathy and thrombosis in cancer. Thrombosis Research, 2022, 213, S72-S76.	0.8	1
275	Venous Gangrene Associated with COVID-19: Successful Limb Preservation Strategies with Optimal Wound Management. Annals of Vascular Surgery Brief Reports and Innovations, 2022, , 100095.	0.1	0
276	Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. Clinical Microbiology and Infection, 2022, , .	2.8	0
277	D-dimer testing in clinical practice in the era of COVID-19. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12730.	1.0	9
278	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. Journal of Clinical Medicine, 2022, 11, 3099.	1.0	13

#	ARTICLE	IF	CITATIONS
279	Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. <i>Journal of Stroke</i> , 2022, 24, 179-188.	1.4	12
280	Prophylactic Anticoagulant Use and Adverse Events with Bleeding in Critically Ill COVID-19 Patients. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2022, 39, 146-157.	0.1	0
281	Antithrombotic agents in patients with COVID-19. <i>Cmaj</i> , 2022, 194, E704-E704.	0.9	1
282	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	15.2	39
283	The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients. <i>Jurnal Respirasi</i> , 2022, 8, 119-125.	0.1	0
284	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	0.5	0
285	Anticoagulation in hospitalized patients with COVID-19. <i>Blood</i> , 2022, 140, 809-814.	0.6	12
286	Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	3
287	Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children. <i>Current Opinion in Pediatrics</i> , 2022, 34, 261-267.	1.0	4
288	Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. <i>Circulation Journal</i> , 2022, 86, 1137-1142.	0.7	4
289	Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. <i>American Journal of Emergency Medicine</i> , 2022, 58, 84-88.	0.7	0
290	Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211038.	0.7	4
292	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <i>Acta Anaesthesiologica Belgica</i> , 2022, 73, 5-14.	0.0	0
293	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Rationale and proposal. <i>Transfusion</i> , 2022, 62, .	0.8	2
294	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 700-714.	5.2	22
295	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 284-308.	1.4	9
296	Redefining critical illness. <i>Nature Medicine</i> , 2022, 28, 1141-1148.	15.2	136
297	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update. , 0, , .		1

#	ARTICLE	IF	CITATIONS
298	Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 541-550.	0.5	0
299	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. Annals of Internal Medicine, 2022, 175, HO2-HO3.	2.0	1
300	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Ethical and regulatory considerations. Transfusion, 2022, 62, .	0.8	2
301	An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Planning and execution. Transfusion, 2022, 62, .	0.8	2
302	Special Issue on "Disseminated Intravascular Coagulation: Current Understanding and Future Perspectives". Journal of Clinical Medicine, 2022, 11, 3315.	1.0	0
303	Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. BMC Emergency Medicine, 2022, 22, .	0.7	0
304	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. Journal of the American College of Cardiology, 2022, , .	1.2	7
305	Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. Thrombosis Journal, 2022, 20, .	0.9	1
306	COVID-19 coagulopathy " what should we treat?. Experimental Physiology, 2022, 107, 749-758.	0.9	8
307	Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 1128-1136.	0.9	4
308	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation: Cardiovascular Quality and Outcomes, 0, , .	0.9	5
309	Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE COVID-19 Registry. Journal of the American Heart Association, 2022, 11, .	1.6	8
310	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	2.5	21
311	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	3.1	22
312	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2022, 9, .	0.4	4
313	COVID Coagulopathy and Thrombosis: A Systematic Review. Touch Reviews in Oncology & Haematology, 2022, 18, 78.	0.1	2
314	Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. Viruses, 2022, 14, 1427.	1.5	1
315	Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study. Journal of Blood Medicine, 0, Volume 13, 363-372.	0.7	1

#	ARTICLE	IF	CITATIONS
316	Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
317	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2022, 17, 1817-1825.	1.0	8
318	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. <i>Blood Advances</i> , 2022, 6, 4710-4714.	2.5	5
319	Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. <i>Lancet Haematology</i> , 2022, 9, e594-e604.	2.2	38
320	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. <i>Annals of Epidemiology</i> , 2022, , .	0.9	2
321	Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, , 101121.	0.6	2
322	The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 715-722.	0.5	1
323	COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	25
324	The Application of Bayesian Methods to Help Interpret the VANCO Trial Results. <i>Journal of Orthopaedic Trauma</i> , 2022, Publish Ahead of Print, .	0.7	2
325	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
326	Thromboprophylaxis in people hospitalized with COVID-19: Assessing intermediate or standard doses in a retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
327	Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 107, 252-259.	0.6	1
328	Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. <i>Critical Care</i> , 2022, 26, .	2.5	11
329	Bleeding and clotting while supported with ECMO: time to move forward. <i>Intensive Care Medicine</i> , 0, , .	3.9	1
330	Venous Thromboembolism in Sepsis: From Bench to Bedside. <i>Biomedicines</i> , 2022, 10, 1651.	1.4	5
331	Optimizing the Design and Analysis of Future AKI Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1459-1470.	3.0	17
332	Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. <i>PLoS ONE</i> , 2022, 17, e0269466.	1.1	3
333	Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism. <i>Hospital Pharmacy</i> , 0, , 001857872211117.	0.4	1

#	ARTICLE	IF	CITATIONS
334	Heart failure in general and cardiac transplant patients with COVID-19. World Journal of Cardiology, 2022, 14, 392-402.	0.5	0
335	3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. Journal of Clinical Medicine, 2022, 11, 3949.	1.0	2
336	Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 2226-2236.	1.9	23
337	Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ, The, 0, , e070022.	3.0	7
338	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. Thrombosis Update, 2022, 8, 100117.	0.4	1
339	Bleeding and thrombotic complications in patients with severe COVID-19: A prospective observational study. Health Science Reports, 2022, 5, .	0.6	3
340	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of Hepatology, 2022, 77, 1161-1197.	1.8	46
341	Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. , 2022, 4, e0727.		3
342	Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	9
343	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics, 2022, 19, 1435-1466.	2.1	22
344	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. Open Forum Infectious Diseases, 2022, 9, .	0.4	6
345	Patients with myeloproliferative neoplasms and COVID-19 have increased rates of arterial thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12752.	1.0	3
346	Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVID-19. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	1
347	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. Frontiers in Pharmacology, 0, 13, .	1.6	8
348	Thromboprophylaxis for children hospitalized with COVID-19 and MIS. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	1.0	6
349	Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice and Research in Clinical Haematology, 2022, 35, 101377.	0.7	3
350	Cardiovascular Complications of Pregnancy-Associated COVID-19 Infections. , 2022, 1, 100057.		6
351	Ability of IMPROVE and IMPROVE-DD scores to predict outcomes in patients with severe COVID-19: a prospective observational study. Scientific Reports, 2022, 12, .	1.6	1

#	ARTICLE	IF	CITATIONS
352	Otolaryngology consultations for COVID-19 patients: A retrospective cohort study of indications, interventions, and considerations. <i>Auris Nasus Larynx</i> , 2022, , .	0.5	0
353	Empiric Anticoagulation Therapy in Hospitalized COVID-19 Patients: An Evaluation of Bleeding Risk Scores Performances in Predicting Bleeding Events. <i>Journal of Clinical Medicine</i> , 2022, 11, 4965.	1.0	2
354	The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2023, 60, 25-40.	2.7	4
356	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	3
357	The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1095-1105.	1.3	2
358	Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2022, 182, 1063.	2.6	48
359	Care of the Seriously Ill Patient with SARS CoV-2. <i>Medical Clinics of North America</i> , 2022, , .	1.1	1
360	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	76
361	Handgrip strength is associated with adverse outcomes in patients hospitalized for COVID-19-associated pneumonia. <i>Internal and Emergency Medicine</i> , 2022, 17, 1997-2004.	1.0	8
362	A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
363	Antithrombotiques chez les patients atteints de COVID-19. <i>Cmaj</i> , 2022, 194, E1074-E1075.	0.9	0
364	Coronavirus Disease 2019-Associated Coagulopathy. <i>Microorganisms</i> , 2022, 10, 1556.	1.6	8
365	Hyperkalemia: do you forget something?. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	0
366	Deep Learning-Based Time-to-Death Prediction Model for COVID-19 Patients Using Clinical Data and Chest Radiographs. <i>Journal of Digital Imaging</i> , 2023, 36, 178-188.	1.6	6
367	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	5
368	Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation. <i>Journal of Clinical Epidemiology</i> , 2022, 151, 96-103.	2.4	5
369	Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2022, 7, 60-62.	0.5	0
370	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. <i>International Journal of Hematology</i> , 2022, 116, 937-946.	0.7	11

#	ARTICLE	IF	CITATIONS
371	Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 420-430.	1.0	17
372	Supportive Care in Patients with Critical COVID-19. <i>Infectious Disease Clinics of North America</i> , 2022, , .	1.9	0
373	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222.	0.8	3
374	Novel Strategies for the Treatment of COVID-19. <i>Drugs in R and D</i> , 2022, 22, 257-262.	1.1	5
375	Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19. <i>EBioMedicine</i> , 2022, 83, 104229.	2.7	13
376	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10372.	1.8	3
377	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. <i>TH Open</i> , 2022, 06, e408-e420.	0.7	5
379	Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. <i>Thrombosis Research</i> , 2022, 219, 95-101.	0.8	5
380	Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 219, 40-48.	0.8	12
381	Effect of combining anticoagulant and glucocorticoid therapy on mortality in patients with severe COVID-19. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2211009.	0.2	0
382	Letter to the Editor: Venous Thromboembolism in COVID-19: Are Women Different?. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 0, 07, 007-008.	0.1	0
383	Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211163.	0.7	2
384	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. <i>Carbohydrate Polymers</i> , 2023, 299, 120167.	5.1	8
385	Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220041.	0.4	3
386	Standardization of D-dimer reporting in the COVID-19 era. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
387	Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. <i>Circulation</i> , 2022, 146, 1344-1356.	1.6	39
388	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <i>Herald of the Russian Academy of Sciences</i> , 2022, 92, 430-436.	0.2	0
389	A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. <i>Global Health & Medicine</i> , 2022, 4, 233-236.	0.6	1

#	ARTICLE	IF	CITATIONS
390	Rotational thromboelastometry in critically ill COVID-19 patients does not predict thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12798.	1.0	3
391	Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 5147.	1.0	28
392	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution? A narrative review. <i>Journal of Bio-X Research</i> , 2022, 5, 97-103.	0.3	1
393	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. <i>Journal of Clinical Medicine</i> , 2022, 11, 4896.	1.0	15
394	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 983-984.	0.3	2
395	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538.	3.9	13
396	Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. <i>European Respiratory Journal</i> , 2023, 61, 2201117.	3.1	8
397	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. <i>Clinics and Practice</i> , 2022, 12, 766-781.	0.6	2
398	Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 5632.	1.0	5
399	Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	2
400	Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies. <i>Vascular</i> , 2024, 32, 220-225.	0.4	0
401	Correlating drug prescriptions with prognosis in severe COVID-19: first step towards resource management. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	1
402	Thromboprophylaxis in Patients With Cancer and COVID-19. <i>Archivos De Bronconeumologia</i> , 2022, 58, 744-745.	0.4	0
403	Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 850-857.	1.5	4
404	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	5
405	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 2194.	1.4	0
406	Development and Implementation of the National Heart, Lung, and Blood Institute COVID-19 Common Data Elements. <i>Journal of Clinical and Translational Science</i> , 0, , 1-25.	0.3	0
407	Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas. <i>ESC Heart Failure</i> , 2022, 9, 3713-3736.	1.4	12

#	ARTICLE	IF	CITATIONS
408	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021â€“2022. <i>Jammi, 2022, 7, 163-169.</i>	0.3	0
409	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. <i>Frontiers in Pharmacology, 0, 13, .</i>	1.6	1
411	Against Therapeutic Anticoagulation in Critically Ill COVID-19 Patients. <i>Seminars in Thrombosis and Hemostasis, 2023, 49, 079-080.</i>	1.5	3
412	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs, 2022, 31, 995-1015.</i>	1.9	4
413	COVID-19 outcomes in sickle cell disease and sickle cell trait. <i>Best Practice and Research in Clinical Haematology, 2022, 35, 101382.</i>	0.7	1
414	Predictors of fatal neurological complications among admitted COVID-19 patients with their implication in outcome: A Case Control study. <i>PLoS ONE, 2022, 17, e0274485.</i>	1.1	1
415	COVID-19 Thrombotic Complications and Therapeutic Strategies. <i>Annual Review of Medicine, 2023, 74, 15-30.</i>	5.0	4
416	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. <i>Frontiers in Medicine, 0, 9, .</i>	1.2	10
417	The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants. , 2022, 2, 148-166.		0
418	Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. <i>Thrombosis Journal, 2022, 20, .</i>	0.9	7
419	Care for adults with <scp>COVID</scp> â€“19: living guidelines from the National <scp>COVID</scp> â€“19 Clinical Evidence Taskforce. <i>Medical Journal of Australia, 2022, 217, 368-378.</i>	0.8	8
420	Prevalence of Venous Thromboembolism and Anticoagulant Use in Patients with COVID-19 in Alberta, Canada. <i>Canadian Journal of Hospital Pharmacy, 2022, 75, 286-293.</i>	0.1	0
421	Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. <i>Thrombosis and Haemostasis, 2023, 123, 186-191.</i>	1.8	4
423	The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review. <i>Cureus, 2022, , .</i>	0.2	1
424	Japanese rapid/living recommendations on drug management for <scp>COVID</scp>â€“19: updated guidelines (July 2022). <i>Acute Medicine & Surgery, 2022, 9, .</i>	0.5	6
425	Tissue plasminogen activator resistance is an early predictor of posttraumatic venous thromboembolism: A prospective study from the CLOTT research group. <i>Journal of Trauma and Acute Care Surgery, 2022, 93, 597-603.</i>	1.1	9
426	Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury. <i>Scientific Reports, 2022, 12, .</i>	1.6	0
427	Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. <i>Frontiers in Immunology, 0, 13, .</i>	2.2	5

#	ARTICLE	IF	CITATIONS
428	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. <i>Biomedicines</i> , 2022, 10, 2620.	1.4	6
429	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1169-1177.	5.2	14
430	COVID-19 Induces Cytokine Storm and Dysfunctional Hemostasis. <i>Current Drug Targets</i> , 2022, 23, 1603-1610.	1.0	3
431	Venous thromboembolism in critically ill patients with pneumonia in the COVID-19 era: Data from a large public database. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	0
432	Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation. <i>Current Drug Targets</i> , 2022, 23, .	1.0	3
433	Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism. <i>Journal of Clinical Medicine</i> , 2022, 11, 6011.	1.0	2
434	Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis. <i>Journal of Hematology (Brossard, Quebec)</i> , 2022, 11, 167-175.	0.4	0
435	Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides. <i>Glycobiology</i> , 0, , .	1.3	1
436	Thrombosis-Related Loss of Arterial Lines in the First Wave of COVID-19 and Non-COVID-19 Intensive Care Unit Patients. <i>Anesthesia and Analgesia</i> , 0, Publish Ahead of Print, .	1.1	1
437	Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome. <i>Russian Journal of Bioorganic Chemistry</i> , 2022, 48, 1109-1122.	0.3	2
439	Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review. <i>Thrombosis Research</i> , 2023, 232, 151-159.	0.8	1
440	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832.	1.5	12
441	Treatment of severe COVID-19: an evolving paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1887-1891.	0.9	5
442	Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. <i>Viruses</i> , 2022, 14, 2330.	1.5	0
443	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
444	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
445	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 5997.	1.0	13
446	Bivalirudin vs. Enoxaparin in Intubated COVID-19 Patients: A Pilot Multicenter Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 5992.	1.0	2

#	ARTICLE	IF	CITATIONS
447	Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. <i>Acta Haematologica</i> , 2023, 146, 151-160.	0.7	0
448	COVID-19 Therapeutics and Considerations for Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, , .	0.7	0
450	Thromboembolic and bleeding events in <scp>ICU</scp> patients with <scp>COVID</scp> â€“19 â€“a nationwide, observational study. <i>Acta Anaesthesiologica Scandinavica</i> , 0, , .	0.7	3
451	COVID tracheostomy complications: A scoping review. <i>Journal of Laryngology and Otology</i> , 0, , 1-31.	0.4	0
452	Modulation of thromboinflammation in hospitalized COVIDâ€“19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWNâ€“Antico study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12826.	1.0	2
453	Therapeutic vs prophylactic anticoagulation in COVID-19 patients: a systematic review and meta-analysis of real-world studies. <i>Minerva Cardiology and Angiology</i> , 0, , .	0.4	1
454	Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, S51-S65.	0.3	0
455	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitaminâ€“Drug Interactions Exist?. <i>Life</i> , 2022, 12, 1654.	1.1	1
456	Machine Learning Approaches for Phenotyping in Cardiogenic Shock andâ€“Critical Illness. , 2022, 1, 100126.		8
457	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211378.	0.7	0
458	Coagulation Abnormalities in Patients with COVID-19. , 2022, , 141-156.		0
459	Venous thromboembolism: Why is it still a significant health problem?. <i>Advances in Medical Sciences</i> , 2023, 68, 10-20.	0.9	3
460	Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. <i>The Journal of Critical Care Medicine</i> , 2022, 8, 249-258.	0.3	0
461	Pediatric Critical Care in the Twenty-first Century and Beyond. <i>Critical Care Clinics</i> , 2022, , .	1.0	0
464	Intensity of anticoagulant dosing in hospitalized patients with COVIDâ€“19: an observational, comparative effectiveness study. <i>Journal of Hospital Medicine</i> , 0, , .	0.7	1
465	Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients. <i>Medicina (Lithuania)</i> , 2022, 58, 1649.	0.8	0
466	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. <i>Thrombosis Update</i> , 2022, , 100126.	0.4	0
468	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24

#	ARTICLE	IF	CITATIONS
469	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. <i>Journal of the Neurological Sciences</i> , 2022, 443, 120487.	0.3	13
470	Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	1
472	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2023, 32, 106904.	0.7	1
473	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5
474	Practice of Awake Prone Positioning in Critically Ill COVID-19 Patients—Insights from the PRoAcT—COVID Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6988.	1.0	2
475	Characteristics and Outcomes of Critically Ill Pregnant/Postpartum Women with COVID-19 Pneumonia in Western Balkans, The Republic of Srpska Report. <i>Medicina (Lithuania)</i> , 2022, 58, 1730.	0.8	2
476	COVID-19 and Pulmonary Thrombosis—An Unresolved Clinical Puzzle: A Single-Center Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 7049.	1.0	3
477	Impact of COVID-19 on Non-Pulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
478	Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. <i>PLoS ONE</i> , 2022, 17, e0277544.	1.1	5
479	Pathophysiology of Hypoxemia in COVID-19 Lung Disease. <i>Clinics in Chest Medicine</i> , 2023, 44, 239-248.	0.8	3
480	Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
481	Platform trials for anaesthesia and perioperative medicine: a narrative review. <i>British Journal of Anaesthesia</i> , 2023, 130, 677-686.	1.5	3
482	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1
484	The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition. <i>Acta Haematologica</i> , 2023, 146, 137-143.	0.7	0
485	The potential impact of nanomedicine on COVID-19-induced thrombosis. <i>Nature Nanotechnology</i> , 2023, 18, 11-22.	15.6	6
486	The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. <i>Blood</i> , 0, , .	0.6	2
487	Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 39.	3.8	64
488	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <i>Trials</i> , 2022, 23, .	0.7	4

#	ARTICLE	IF	CITATIONS
490	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
491	COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample. <i>Vaccines</i> , 2022, 10, 2104.	2.1	4
493	COVID-19 drug-induced liver injury: A recent update of the literature. <i>World Journal of Gastroenterology</i> , 0, 28, 6314-6327.	1.4	5
494	Thrombosis questions from the inpatient wards. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 481-490.	0.9	1
495	A Bayesian Interpretation of a Pediatric Cardiac Arrest Trial (THAPCA-OH). , 2023, 2, .		8
496	To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 506-514.	0.9	4
497	Major Publications in the Critical Care Pharmacotherapy Literature: 2021. , 2022, 4, e0823.		1
498	Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962211484.	0.7	5
499	Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study. <i>PLoS ONE</i> , 2023, 18, e0267339.	1.1	0
500	Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). <i>Contemporary Cardiology</i> , 2022, , 243-254.	0.0	0
501	Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>American Heart Journal</i> , 2023, 258, 149-156.	1.2	3
502	Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. <i>Annals of Vascular Diseases</i> , 2023, , .	0.2	0
503	Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. <i>J. Clin. Med.</i> 2022, 11, 860. <i>Journal of Clinical Medicine</i> , 2023, 12, 478.	1.0	1
504	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	2.1	7
505	Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19. <i>Diagnostics</i> , 2023, 13, 224.	1.3	0
506	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome – Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
508	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2023, 18, 863-877.	1.0	2
509	Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. <i>Surgical Infections</i> , 2023, 24, 6-18.	0.7	4

#	ARTICLE	IF	CITATIONS
511	Thromboprophylaxis in COVID-19. <i>Medicina Interna (Bucharest, Romania)</i> , 2022, 19, 59-69.	0.1	0
513	Antithrombotic therapy in COVID-19 patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2023, 16, 718-731.	0.2	1
514	Chronic anti-coagulation therapy reduced mortality in patients with high cardiovascular risk early in COVID-19 pandemic. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
515	COVID-19 and atrial fibrillation: Intercepting lines. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	11
516	Electrical Impedance Tomography As a Bedside Diagnostic Tool for Pulmonary Embolism. , 2023, 5, e0843.		3
517	The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. , 2023, 2, .		0
518	Microvascular Thrombosis as a Critical Factor in Severe COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2492.	1.8	10
519	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301.	2.8	0
520	Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis. <i>Journal of Trauma and Acute Care Surgery</i> , 2023, 94, 513-524.	1.1	5
521	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0274243.	1.1	0
522	Distribution of aeration and pulmonary blood volume in healthy, ARDS and COVID-19 lungs: a dual-energy computed tomography retrospective cohort study. <i>Academic Radiology</i> , 2023, , .	1.3	0
523	Recent advances in critical care. <i>Medical Journal of Australia</i> , 2023, 218, 153-156.	0.8	0
524	International platform trials: as diseases cross borders, so should trials. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 530-531.	4.6	0
525	Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial. <i>Thrombosis Research</i> , 2023, 224, 13-16.	0.8	0
527	Thromboembolic Events in COVID-19. <i>Contemporary Cardiology</i> , 2022, , 201-216.	0.0	0
528	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. <i>BMJ Open</i> , 2023, 13, e066218.	0.8	3
529	The Efficacy and Safety of Prolonged Oral Anticoagulation for the Prevention of Thromboembolic Events in Patients Recovered From COVID-19 1 Year After Hospital Discharge: The SARCOV-19 Prospective Registry. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311517.	0.7	1
530	Therapeutic options in COVID-19. , 2023, , 647-672.		0

#	ARTICLE	IF	CITATIONS
531	Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment. <i>Pharmaceuticals</i> , 2023, 16, 271.	1.7	1
532	Pharmacology of Heparin and Related Drugs: An Update. <i>Pharmacological Reviews</i> , 2023, 75, 328-379.	7.1	16
533	MICHELLE trial: Inching towards the holy grail of post-discharge anticoagulation in Covid-19!. <i>The National Medical Journal of India</i> , 0, 35, 290-292.	0.1	0
535	Extracardiac Prothrombotic Effects of COVID-19. <i>Heart Failure Clinics</i> , 2023, 19, 213-220.	1.0	0
536	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. <i>Cells</i> , 2023, 12, 778.	1.8	6
538	In Situ Pulmonary Arterial Thrombosis: Literature Review and Clinical Significance of a Distinct Entity. <i>American Journal of Roentgenology</i> , 2023, 221, 57-68.	1.0	6
540	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	1
541	Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study*. <i>Critical Care Medicine</i> , 2023, 51, 619-631.	0.4	7
542	Interactions between the renin-angiotensin-aldosterone system and COVID-19. , 2023, , 355-373.		0
543	Retroperitoneal hematoma: An unexpected complication of anticoagulant therapy in COVID-19 patients. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2023, , 23-23.	0.1	0
544	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
545	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1747-1762.	1.2	24
546	Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712.	1.1	2
547	Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach. <i>PLoS ONE</i> , 2023, 18, e0282587.	1.1	0
549	Anti-cytokine Therapy in Critical Illness: Is There a Role?. <i>Lessons From the ICU</i> , 2023, , 277-297.	0.1	0
550	Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2023, 147, .	1.6	12
551	Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. <i>JAMA Network Open</i> , 2023, 6, e232338.	2.8	7
552	The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	0

#	ARTICLE	IF	CITATIONS
553	Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 2222.	1.0	0
554	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. <i>North Carolina Medical Journal</i> , 2023, 84, .	0.1	0
555	Montelukast as a potential treatment for COVID-19. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 551-555.	0.9	1
556	Immunothrombosis and COVID-19 â€” a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital. <i>Clinics</i> , 2023, 78, 100178.	0.6	0
557	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: FundamentaÃ§Ã£o e Desenho do Estudo CARE (CARE â€” Coalition COVID-19 Brazil VIII). <i>Arquivos Brasileiros De Cardiologia</i> , 2023, 120, .	0.3	1
558	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1066.	3.8	25
559	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2023, 183, 520.	2.6	11
560	Anticoagulation in Patients With COVID-19 Pneumoniaâ€”What Is the Optimal Intensity?. <i>JAMA Internal Medicine</i> , 2023, 183, 532.	2.6	3
561	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. <i>Canadian Journal of Cardiology</i> , 2023, 39, 865-874.	0.8	2
562	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	2
563	D-dimer testing: A narrative review. <i>Advances in Clinical Chemistry</i> , 2023, , 151-223.	1.8	1
564	Approaches to Assure Similarity between Pharmaceutical Heparins from Two Different Manufacturers. <i>Pharmaceutics</i> , 2023, 15, 1115.	2.0	2
565	Pathophysiology of COVID-19 pneumonia and respiratory treatment. <i>Minerva Anestesiologica</i> , 2023, 89, .	0.6	1
566	Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study. <i>Vascular</i> , 0, , 170853812311650.	0.4	0
567	Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105.	0.6	1
568	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Supportâ€”Free Days in Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1183.	3.8	19
569	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 688-691.	0.4	0
570	Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7278.	1.8	4

#	ARTICLE	IF	CITATIONS
571	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. <i>Thrombosis Journal</i> , 2023, 21, .	0.9	0
591	Continuation of therapeutic dose heparin for critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2023, 49, 873-875.	3.9	3
647	Using autopsies to dissect COVID-19 pathogenesis. <i>Nature Microbiology</i> , 2023, 8, 1986-1994.	5.9	3
691	COVID-19 und VTE-Prophylaxe. <i>Springer Reference Medizin</i> , 2024, , 1-11.	0.0	0
692	Oral Infections, SARS-CoV-2 Infection, and Autoimmunity. , 2024, , 1013-1044.		0